Pacira BioSciences (PCRX) News Today

Dimensional Fund Advisors LP increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 12.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,828,065 shares of th

Marshall Wace LLP lifted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 19.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 971,143 shares of the company's stock after b

Doma Perpetual Capital Management LLC boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 71.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,000,761 shares of the comp

Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday.

Pacer Advisors Inc. raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 37.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,162,787 shares of the company's stock after buyin

Renaissance Technologies LLC boosted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 9.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,066,197 shares of the company's stock after buying an additional 184,000

Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 6.7%

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 6,050,000 shares, a growth of 17.5% from the August 15th total of 5,150,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 4.5 days.

Pacira BioSciences (NASDAQ:PCRX) Sees Large Volume Increase

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been given a consensus recommendation of "Hold" by the nine brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given

WINTON GROUP Ltd acquired a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 95,266 shares of the company's stock, valued at approximately

Thornburg Investment Management Inc. purchased a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 188,590 shares of the company's stock, valued at approximately $5,396,000. T

Rice Hall James & Associates LLC trimmed its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 4.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 998,625 shares of the company's

Pacira BioSciences (NASDAQ:PCRX) Shares Down 4.4%

Lisanti Capital Growth LLC purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 138,830 shares of the company's stock,

Rothschild Investment LLC acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 72,992 shares of the company's stock, valued at a

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) saw a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 5,150,000 shares, a decrease of 18.4% from the July 31st total of 6,310,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is currently 4.0 days.

Banco Santander S.A. acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 138,373 shares of the company's stock, valued at approx

Legato Capital Management LLC lifted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 74.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,913 shares of the company's stock after purch

Baillie Gifford & Co. trimmed its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 19.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 806,097 shares of the company's stock aft

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been given an average recommendation of "Hold" by the nine research firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold reco

Assenagon Asset Management S.A. lowered its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 32.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,458 shares of the company's

Pacira BioSciences (NASDAQ:PCRX) Shares Up 4.6%

Pacira BioSciences (NASDAQ:PCRX) Shares Down 3.7%

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down After Analyst Downgrade

Truist Financial cut shares of Pacira BioSciences from a "buy" rating to a "sell" rating and lowered their target price for the stock from $30.00 to $8.00 in a research note on Tuesday.

StockNews.com cut shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research note on Monday.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) Director Mark Froimson bought 1,400 shares of the business's stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $11.58 per share, for a total transaction of $16,212.00. Following the purchase, the director now owns 14,473 shares in the company, valued at approximately $167,597.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) was the target of some unusual options trading on Monday. Stock investors purchased 4,984 put options on the stock. This represents an increase of 322% compared to the typical volume of 1,182 put options.